News for Aytu Biopharma, Inc. (AYTU)

Operator: Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call. At this time, all participants are in a listen-only.

Net Revenue: $18.5 million, surpassing the estimated $13.74 million, marking a 32% increase year-over-year.Net Income: Achieved $4.0 million, or $0.65 and $0.2

Release Date: May 14, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aytu BioPharma In

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAYTU.OQ - Aytu Biopharma IncQ3 2025 Aytu Biopharma Inc Earnings CallMay 14, 2025 / 08:30PM GMT

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 mi

On February 28, 2025, Joshua Disbrow, the Chief Executive Officer of Aytu BioPharma Inc, purchased 15,000 shares of the company, as reported in a SEC Filing. Fo

**media[548579]**

Release Date: February 12, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aytu BioPhar

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAYTU.OQ - Aytu Biopharma IncQ2 2025 Aytu Biopharma Inc Earnings CallFeb 12, 2025 / 09:30PM GMT

Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase fo

Earnings Call Insights: Aytu BioPharma (NASDAQ:AYTU) Q2 2025Management ViewCEO Josh Disbrow reported that both the ADHD and pediatric portfolios achieved...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ETCompany ParticipantsRobert Blum - Investor Relations, Lytham...

Ironwood Pharmaceuticals (IRWD) recently experienced a significant stock price drop of 5.20%, bringing its share price to $3.58. The trading volume reached 431,

DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing no

SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ( ACHV), a late-stage pharmaceutical company dedicated

**media[487285]**

DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIE

DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsRobert Blum - IR, Lytham PartnersJosh...